Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $18.9M | $0.00 | — | — | — |
| Revenue growth | — | — | -100.0% | — | — | — |
| Operating income | -$60.3M | -$68.0M | $145M | -$191M | -$197M | -$242M |
| Operating margin | — | -358.7% | — | — | — | — |
| Net income | -$51.8M | -$65.6M | $111M | -$153M | -$167M | -$220M |
| Net margin | — | -346.1% | — | — | — | — |
| EPS (diluted) | -$2.60 | -$1.52 | $2.38 | -$3.69 | — | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$29.8M | -$43.4M | -$127M | -$134M | -$145M | -$176M |
| Capital expenditures | $10.0K | $0.00 | $1.13M | $208K | $0.00 | $49.0K |
| Free cash flow | -$29.8M | -$43.4M | -$128M | -$134M | -$145M | -$176M |
| Share buybacks | $6.57M | — | — | — | — | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $168M | $59.8M | $156M | $98.4M | $83.0M | $88.3M |
| Total assets | $215M | $437M | $561M | $484M | $622M | $448M |
| Total liabilities | $14.4M | $11.8M | $26.1M | $30.3M | $31.5M | $39.6M |
| Shareholders' equity | $199M | $425M | $535M | $454M | $590M | $409M |
| Retained earnings | -$93.3M | -$159M | -$47.7M | -$201M | -$368M | -$588M |
| Shares (wtd avg diluted) | 29.8M | 44.3M | 45.8M | 42.9M | 58.5M | 60.2M |
Every figure is extracted from Cullinan Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.